1. Azer-Cel is the further advanced of the IP with FDA IND and path to registrational clinical trial so arguably even more advanced than HER-Vaxx which has completed Ph2 with the final clinical trial result released this year. I think IMU will move OnCARyltic above CF33 as priority if the interim result from this clinical trial update is promising.
2. I guess IMU is seeing efficacy when the clinical trial get expanded like they did with bile duct and mentioned of bladder and neck solid cancer but they haven't released any further clinical trial update for VAXINIA since 9 months ago.
3. These were voted by share holders so I'm not sure why you are surprise?
1. Azer-Cel is the further advanced of the IP with FDA IND and...
-
- There are more pages in this discussion • 137 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.4¢ |
Change
-0.001(0.93%) |
Mkt cap ! $385.8M | |||
| Open | High | Low | Value | Volume |
| 5.4¢ | 5.4¢ | 5.3¢ | $247.2K | 4.649M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 9 | 450821 | 5.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.4¢ | 1767159 | 36 |
View Market Depth
| Last trade - 12.47pm 28/08/2024 (20 minute delay) ? |
| IMU (ASX) Chart |